R&D News | pharmaphorum

News

Failed trial knocks back wider use of BMS' Camzyos

Bristol-Myers Squibb's Camzyos has fallen short in a trial in non-obstructive hypertrophic cardiomyopathy, denting its growth prospects.

News

Scancell taps into NHS matchmaking service for cancer trial

Scancell is using a new service launched by the NHS to pair patients with suitable clinical trials in a phase 2 trial of its melanoma cancer vaccine.

News

Pfizer's weight-loss aspirations are dealt a heavy blow

Pfizer has been forced to discontinue its oral GLP-1 receptor agonist danuglipron after seeing signs of liver toxicity in late-stage clinical testing.

News

Novartis radioligand therapy (RLT) manufacturing facility

Novartis plans $23bn manufacturing, R&D spend in US

Novartis has announced a massive investment in manufacturing and R&D facilities in the US so it can make "100% of its key medicines" there.

News

FDA plans to phase out animal testing for antibodies

The FDA has said it intends to reduce or replace animal testing of some medicines, including monoclonal antibodies, with other methods.

News

Alzheon Alzheimer's hopes dented by trial readout

Alzheon has been left sifting through data from a failed Alzheimer's trial for crumbs of evidence that its oral therapy may have some efficacy.

Failed trial knocks back wider use of BMS' Camzyos

Scancell taps into NHS matchmaking service for cancer trial

Pfizer's weight-loss aspirations are dealt a heavy blow

Novartis plans $23bn manufacturing, R&D spend in US

FDA plans to phase out animal testing for antibodies

Alzheon Alzheimer's hopes dented by trial readout

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks